Home › Merck to Present New Data on ZEPATIER (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting 2016
 

Keywords :   


Merck to Present New Data on ZEPATIER (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting 2016

2016-10-03 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the companys chronic hepatitis C virus (HCV) clinical development programs will be presented at The Liver Meeting 2016. Fifteen scientific abstracts, including seven oral and eight poster presentations, will highlight findings from Mercks HCV clinical development programs. Language: English Contact: MerckMedia:Doris Li, 908-740-1903Ian McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the data development present

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 7
05.11Tropical Storm Rafael Public Advisory Number 7
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 7
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
More »